Moderna to seek U.S. nod for COVID-19 shot in very young kids by April end - Reuters
Maddie Meyer/Getty Images News


Moderna (NASDAQ:MRNA) plans to file for the U.S. Emergency Use Authorization (EUA) for its COVID-19 shot targeted at kids aged six months to five years by end of April, Reuters reported citing a company spokesperson.
The Omicron variant was dominant during the companyâs pediatric trial, and the Cambridge, Mass.-based biotech said that the two-dose vaccine was ~38% and 44% effective in preventing infections among 2 to 5-year-olds and children aged 6 months to under 2 years, respectively.

Currently, the companyâs MRNA-based vaccine, branded as Spikevax, is indicated in the U.S. for the prevention of COVID-19 in individuals aged 18 years and older. It is authorized for use in those aged six years and older in Europe.
Last June, the company sought the FDAâs emergency use authorization (EUA) for the vaccine targeting adolescents.